Good Life Advisors LLC Purchases 1,468 Shares of Pfizer Inc. (NYSE:PFE)

Good Life Advisors LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 31,624 shares of the biopharmaceutical company’s stock after buying an additional 1,468 shares during the quarter. Good Life Advisors LLC’s holdings in Pfizer were worth $910,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Worth Asset Management LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $29,000. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the third quarter valued at $30,000. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC raised its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PFE. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Friday, March 1st. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. UBS Group lowered their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research report on Thursday, December 14th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Finally, Truist Financial decreased their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

Shares of PFE stock traded down $0.03 during trading on Thursday, hitting $27.75. The company’s stock had a trading volume of 39,669,508 shares, compared to its average volume of 43,829,785. The business has a fifty day moving average of $27.47 and a 200-day moving average of $29.47. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The company has a market cap of $157.14 billion, a PE ratio of 77.25, a P/E/G ratio of 1.24 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.